TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers.
Sarepta Therapeutics Inc. (SRPT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,674,835 | $170,707,970 | +5% | 2.66% |
| 2. | Farallon Capital Thomas Steyer | 2,341,424 | $149,429,680 | -19% | 0.83% |
| 3. | EcoR1 Capital Oleg Nodelman | 1,292,386 | $82,480,075 | +68% | 4.89% |
| 4. | Casdin Capital Eli Casdin | 900,783 | $57,487,971 | -17% | 4.7% |
| 5. | Deep Track Capital David Kroin | 899,731 | $57,420,832 | 1.86% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.66 | 5,648 | $760,559.68 | 284,034 | 2024-08-16 | Filing | |
| $134.06 | 18,284 | $2,451,153.04 | 278,386 | 2024-08-16 | Filing | |
| $133.07 | 13,106 | $1,744,015.42 | 260,102 | 2024-08-16 | Filing | |
| $78.81 | 40,000 | $3,152,400.00 | 140,000 | 2023-11-03 | Filing | |
| $78.81 | 10,000 | $788,100.00 | 10,000 | 2023-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.64 | 2,491 | $248,203.24 | 27,812 | 2025-03-12 | Filing | |
| $124.84 | 10,500 | $1,310,820.00 | 22,840 | 2024-12-12 | Filing | |
| $125.55 | 1,636 | $205,399.80 | 5,880 | 2024-12-05 | Filing | |
| $137.36 | 5,985 | $822,099.60 | 33,946 | 2024-08-30 | Filing | |
| $164.52 | 2,549 | $419,361.48 | 17,129 | 2024-06-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 108 | $1,847 | 0% | |
| 2. | 30 | $513 | 0% |
News See All
Sarepta Viral Vector Gets FDA Platform Technology Designation
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now.
Sarepta Therapeutics (SRPT) Tumbles 44% W/W as Analyst Cuts Price Target by 63%
In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent downside.
11 Best Mid Cap Growth Stocks To Invest In Now
On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC's 'Closing Bell Overtime' to talk about how the market sell-off is an opportunity to step in.
10 Worst Aggressive Growth Stocks to Buy According to Short Sellers
According to Morningstar, stocks have experienced a healthy recovery over the past few months. However, the momentum was insufficient to propel the market to a new high for the year.
Sarepta Therapeutics' (SRPT) Rating Downgrade Dents Share Price
We recently published a list of 10 Stocks Investors Dumped Fast.
The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation
The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc.
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?
We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc.
Was Jim Cramer Right About These 11 Stocks?
"We temporarily forgot who was in charge, who determines stock prices, who decides whether we're going to have an up day or a down day. No, I'm not talking about the invisible hand of the market.
Billionaire Glenn Russell Dubin's 10 Stock Picks with Huge Upside Potential
Glenn Russell Dubin is one of the industry's most experienced hedge fund managers, best known as the co-founder of Highbridge Capital Management, a multi-strategy investment business he founded with Henry...
Billionaire Hedge Funds
